Life Sciences Update - March 2017

Life Sciences Update - March 2017

Welcome to our Life Science Issue, a monthly update from the Life Sciences team at S&B, containing news about recent and topical developments.

Contact our experts for further advice

View profile for Charlotte TillettCharlotte Tillett, View profile for Michael FrisbyMichael Frisby, View profile for Gustaf DuhsGustaf Duhs
  1. Medicines for Europe - Legal Affairs conference

    Stevens & Bolton's life sciences partners Beverley Flynn and Michael Frisby had a very enjoyable time meeting up with old friends and new contacts at the Medicines for Europe Legal Affairs conference on 22-23 March.  Many thanks to Medicines for Europe for an interesting and varied programme.

  2. Pharmaceutical Pricing Under the Spotlight

    Recent developments suggest that the competition regulator in the UK has his eye on pharmaceutical pricing. These developments, planned legislative changes in the UK as well as political developments in the US suggest that pharmaceutical companies need to be more prudent than ever when taking decisions on the price of their products.

    Read more - article published in PharmaTimes (P.22)

  3. Brexit: International Arbitration and Life Sciences

    As the UK Government serves notice of departure on the EU, life sciences businesses involved in cross border trade need to ensure that their contracts are enforceable now and post Brexit.  International arbitration is likely to continue to present a reliable option.

    Read more
  4. Focus on pharmaceutical pricing regulation

    The Pharmaceutical Pricing Regulation Scheme (PPRS) sets out to cap the NHS branded medicines bill at a time of severe financial pressure on the health service but has not been as successful as the Government had hoped in delivering savings. We provide a potted guide.

    Read more
  5. Measures to prevent falsified APIs

    The Medicines and Healthcare products Regulatory Agency (MHRA) has published two pieces on its blog about the risk of falsified Active Pharmaceutical Ingredients (APIs) entering the supply chain and Europe-wide measures being taken to prevent this. We provide a quick guide to the key points.

    Read more

Search our site